Invesco Ltd. Increases Holdings in Qiagen N.V. $QGEN

Key Points

• Invesco Ltd. increased its holdings in Qiagen N.V. by 13.5%, acquiring an additional 53,383 shares in the 1st quarter, bringing its total ownership to 449,638 shares valued at approximately $18 million.
• Qiagen reported $0.60 earnings per share for the quarter, matching analysts' expectations, and its revenue increased 7.7% year-over-year to $533.54 million.
• The company declared a quarterly dividend of $0.25 per share, reflecting a substantial yield of 52.0%, with a payout ratio of 14.79%.

Invesco Ltd. boosted its position in Qiagen N.V. (NYSE:QGEN - Free Report) by 13.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 449,638 shares of the company's stock after buying an additional 53,383 shares during the quarter. Invesco Ltd. owned approximately 0.20% of Qiagen worth $18,053,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently made changes to their positions in the company. ANTIPODES PARTNERS Ltd bought a new position in shares of Qiagen during the 1st quarter worth $94,000. Tower Research Capital LLC TRC lifted its holdings in Qiagen by 770.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after purchasing an additional 2,204 shares during the last quarter. GAMMA Investing LLC boosted its position in Qiagen by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock worth $118,000 after purchasing an additional 1,425 shares during the period. Federated Hermes Inc. purchased a new position in shares of Qiagen in the first quarter worth about $150,000. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of Qiagen in the fourth quarter worth about $202,000. 70.00% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on QGEN shares. Bank of America upped their price target on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research note on Thursday, June 26th. Cowen reissued a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Barclays assumed coverage on Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. UBS Group lifted their price target on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research report on Thursday, August 7th. Finally, Wall Street Zen lowered Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Three equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $49.69.

Qiagen Price Performance

Shares of QGEN stock traded up $0.5840 on Friday, reaching $49.7140. The company's stock had a trading volume of 882,883 shares, compared to its average volume of 1,356,347. Qiagen N.V. has a 12-month low of $37.63 and a 12-month high of $51.88. The stock's 50 day simple moving average is $48.61 and its 200-day simple moving average is $43.90. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $11.05 billion, a P/E ratio of 29.37, a PEG ratio of 2.61 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The firm had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company's revenue was up 7.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.55 EPS. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, equities analysts predict that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Qiagen Dividend Announcement

The business also recently declared a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were paid a $0.25 dividend. This represents a yield of 52.0%. The ex-dividend date of this dividend was Wednesday, July 2nd. Qiagen's payout ratio is currently 14.79%.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.